Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: Provided herein are methods for mapping modified nucleotide residues in nucleic acids. The methods include providing a nucleic acid sample in which non-target or target modified and unmodified nucleotide residues are converted to form of a different nucleotide (such a “C” being converted to “T”). Second strand synthesis is then performed on the converted nucleic acids using a set of anchored-base primers. Each primer in the set of anchored-base primers comprises one or more anchor bases at the 3? terminus that are complementary to the target nucleotide (e.g., “G” or “CpG”), and a sequence of nucleotides selected from a set of sequences that could be a fully or partially degenerate set of sequences. For example, the sequence could be 5?-XnG-3? and/or 5?-X(n?1)CG-3?, wherein X is any base, and n=2 to 25. Double-stranded nucleic acid products can be analyzed, for example by amplification and high throughput sequencing.

Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: The present invention provides recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein.

Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response.

Abstract: The invention provides novel methods and materials for genetic and genomic analysis using single or multiplex isolation of protein-associated nucleic acids, including transposase-assisted chromatin immunoprecipitation (TAM-ChIP) and antibody-oligonucleotide proximity ligation. These methods comprise tagging and isolating chromatin or other protein-associated nucleic acids and using antibody-oligonucleotide complexes that recognize the proteins associated with such nucleic acids.

Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: Disclosed herein are compositions, methods and kits useful for epigenetic analysis based on the use of transposons that are targeted to specific regions of chromatin based on DNA-DNA interactions, protein-protein interactions, RNA-RNA interactions, and nucleic acid-protein interactions.

Abstract: Compounds are described and claimed comprising general formula: The compounds have substituents as described herein and are useful, e.g., for their ability to bind nucleic acids and thereby effect purifications, probing techniques and gene inhibition.

Abstract: A bioanalytical method for determining catalases and peroxidases using europium ions.

Abstract: The present invention concerns biological methods of determination using enzymes from the group of oxidases and using optical indicators from the group of lanthanoid-ligand complexes.

Abstract: The present invention relates generally to oligonucleotide analogues that include novel protein nucleic acid molecules (PNAs), particularly monomers, dimers, oligomers thereof and methods of making and using these oligonucleotide analogues. The PNAs of the present invention are characterized as including a variety of classes of molecules, such as, for example, hydroxyproline peptide nucleic acids (HypNA), and serine peptide nucleic acids (SerNA). The invention includes monomers, homodimers, heterodimers, homopolymers and heteropolymers of these and other oligonucleotide analogues. The present invention includes methods of using these oligonucleotide analogues in the detection and separating of nucleic acid molecules, including uses that include the utilization of oligonucleotide analogues on a solid support. The present invention also includes methods for purifying or separating nucleic acids, such as mRNA molecules, by hybridization with the oligonucleotides of the present invention.

Abstract: Peptides that are useful as transfection agents are described. The peptides can facilitate the efficient cellular internalization of a broad range and size of compounds that when non-covalently complexed therewith are efficiently internalized into a cell. Advantages include but are not limited to excellent transfection efficiency, relatively low toxicity, internalization by a broad host cell spectrum, and the simplicity and cost-effectiveness that arise from not having to covalently complex the peptide with a specific molecule to be delivered. Applications include but are not limited to the delivery of diagnostics and therapeutics, as well as drug discovery, gene discovery, and the analysis and/or manipulation of other cellular and molecular biological functions. Claims are made for transfection agents, compositions of matter, including pharmaceutical compositions, reagent kits, methods of delivery, and methods of identification of additional peptides for performing and/or including in the same.